Hepatitis C Treatment Granted Breakthrough Designation
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that grazoprevir/elbasvir, an investigational single tablet regimen for the treatment of chronic hepatitis C virus (HCV) infection, has received two new Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic HCV genotype 4 (GT4) infection, and for the treatment of chronic HCV genotype 1 (GT1) infection in patients with end stage renal disease on hemodialysis. Additionally, the company announced presen...
New Warnings for Hepatitis C Rx
Taken with a heart medication, two hepatitis C drugs might pose some serious health risks.
When Delaying Treatment Could Cost You More Dough
The cost of treating a chronic disease can add up, sometimes leading patients to hold off until the disease progresses. The most cost-effective way to treat a common liver condition, however, might be to face it head on.
Anti-Herpes Rx Did Double Duty
Genital herpes and HIV are similar in that both are sexually transmitted viruses — and now it looks as though they might also respond to the same medication.
No Shortage of Hepatitis C Treatments
In the last three years, there have been many advances in treating hepatitis C, which can not only offer patients more treatment options but also shorter treatment times.
Experimental Rx May Cure Hepatitis C in Six Weeks
Achillion Pharmaceuticals Inc. announced today that its experimental hepatitis C treatment may be able to reverse hepatitis C in as little as six weeks.
Breathe Easy, Parents: Vaccine Not Tied to More STDs
Some parents have raised concerns that vaccinating young girls against HPV, a sexually transmitted illness, might lead to more unsafe sexual activity in these girls. New evidence, however, suggests that's not the case — and the vaccine could prevent serious health problems.
Achillion Achieves 100% SVR12 in Phase 2 Trial
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced updated interim results from the ongoing interferon-free, ribavirin-free, Phase 2 study to evaluate the efficacy, safety, and tolerability of six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a marketed nucleotide polymerase inhibitor, in treatment-naïve genotype 1 HCV-infected patients.
This Hep C Rx Combo May Be Quicker Cure
For people with hepatitis C, three isn't a crowd. These patients got well much faster with the addition of a third medication.
New Test May Replace Pap Smear as Initial Screen
Pap smears may be passé for some women. A new cervical cancer test may be coming into vogue.